

Ref: SPL/CORP-SEC/2026-27/BSE/169

Dated:11.08.2026

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting held on 11TH August 2026 with Scrip Code 524703.

Ref: Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

A Meeting of the Board of Directors of the Company duly convened on Tuesday, 11th August 2026 at 04:00 p.m. and concluded at 5.15 p.m. discussed the following business: -

1. Financial Results

Approved the Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2026, as placed before the Board, along with the Limited Review Report thereon issued by the Statutory Auditors of the Company, expressing an unmodified conclusion. The said Unaudited Standalone Financial Results, together with the Limited Review Report, were duly considered, approved and taken on record by the Board of Directors.

2. Approved the Directors' Report, Management Discussion and Analysis Report, Corporate Governance Report, Secretarial Audit Report and other reports forming part of the Annual Report of the Company for the financial year ended March 31, 2026, as placed before the Board. The Board duly considered and approved the same for inclusion in the Annual Report of the Company for the financial year 2025-26 and for circulation to the Members in connection with the ensuing Annual General Meeting.

3. Record Date

Approved the closure of the Register of Members and Share Transfer Books of the Company from Friday, September 4, 2026 to Friday, September 11, 2026, both days inclusive, in connection with the ensuing Annual General Meeting of the Company. The Record Date for determining the eligibility of Members entitled to receive the proposed dividend for the financial year ended March 31, 2026 shall be Friday, September 4, 2026.

4. Took note of the Statement of Utilisation and Statement of Deviation(s) in utilisation of funds, if any, as required under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended June 30, 2026.

5. Notice of Annual General Meeting

Approved the convening of the 41st Annual General Meeting (“AGM”) of the Company to be held on Friday, September 11, 2026, at 4:30 P.M. (IST) through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”), in accordance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

6. Material Related Party Transactions

Recommended the proposal for obtaining the approval of the Members at the ensuing Annual General Meeting for the continuation of the Material Related Party Transactions entered into/proposed to be entered into with M/s. Sandu Brothers Private Limited, in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time. The Board, after considering the relevant details and terms of the proposed transactions, recommended the same for approval of the Members at the ensuing Annual General Meeting.

7. Appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors of the Company for a first term of five consecutive years.

The Board of Directors, based on the recommendation of the Audit Committee, approved and recommended the appointment of M/s. Dave & Dave, Chartered Accountants (Firm Registration No. 102163W), holding Peer Review Certificate No. 020259, as the Statutory Auditors of the Company for a first term of five consecutive years, commencing from the conclusion of the ensuing Annual General Meeting and continuing until the conclusion of the Annual General Meeting to be held in the year 2031, subject to the approval of the Members of the Company at the ensuing Annual General Meeting.

The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is disclosed as Annexure I.

For Sandu Pharmaceuticals Limited



Pratika Mhambray
Company Secretary
ACS :36512

Annexure I

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026

Sr No	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Appointment of statutory auditor for first term of 05 years
2.	Date of appointment/ Cessation and terms of appointment;	Date of Reappointment 11.08.2026 Term of appointment: For a period of five (5) consecutive financial years commencing from Financial Year 2026-27 to Financial Year 2030-31, subject to approval of the Members at the ensuing Annual General Meeting and to hold office until the conclusion of the Annual General Meeting to be held in the year 2031.
3.	Brief Profile (in case of appointment);	M/s. Dave & Dave, Chartered Accountants, is a partnership firm established in 1989 and registered with the Institute of Chartered Accountants of India (ICAI) under Firm Registration No. 102163W. The firm is based in Mumbai and has 2 partners, 2 associates and 10 other staff members. The firm has a valid Peer Review Certificate No. 020259, valid from 25 March 2025 to 31 March 2028. The firm has extensive experience in statutory, internal, management, stock and tax audits, along with services relating to corporate law and secretarial compliances, taxation, project financing, accounting and valuation. The partners of the firm have significant professional experience, with experience ranging from 25 to 35 years in taxation, audit, project finance and GST audit. The firm has also rendered professional services to various listed companies, private companies, public sector undertakings and banking institutions.
4.	Disclosure of relationships between directors. (in case of Appointment)	M/s. Dave & Dave, Chartered Accountants, is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

FOR SANDU PHARMACEUTICALS LIMITED.



Pratika Mhambray
Company Secretary
ACS : 36512



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL
RESULTS FOR THE QUARTER ENDED ON 30th JUNE 2026**

To,

**The Board of Directors,
Sandu Pharmaceuticals Limited,**
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

Dear Sirs,


1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter ended on 30th June, 2026, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (*SRE*) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi

Chartered Accountants

Firm Registration Number: 122290W



Himmat Mali

(Partner)

Membership Number: 183378

UDIN-26183378OLMYXL4733




Place: Mumbai

Date: 11th August, 2026

SANDU PHARMACEUTICALS LIMITED
Standalone Statement of Profit and Loss for the Period ended 30th June, 2026

Particulars	(Rs in lakhs)			
	3 Months ended	Preeceding 3 Months	Corresponding 3	Year ended
	30th June 2026	Ended	Months ended	31st March 2026
	Unaudited	Audited	Unaudited	Audited
INCOME				
Revenue From Operations	1638.88	1685.34	1669.90	6993.45
Other Income	1.74	36.51	1.77	44.44
Total Income	1640.62	1721.85	1671.67	7037.89
EXPENSES				
Cost of materials consumed	234.10	383.94	191.08	1101.18
Purchases of Stock-in-Trade	443.24	351.54	358.75	1648.07
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-23.36	-83.01	333.47	407.95
Employee benefits expense	279.45	274.28	266.36	1069.08
Finance costs	2.99	2.56	2.64	11.21
Depreciation and amortization expense	16.37	16.49	17.76	67.70
Other expenses	651.78	701.34	467.73	2467.16
Total expenses	1604.57	1647.14	1637.80	6772.35
Profit/(loss) before exceptional items and tax	36.05	74.71	33.87	265.54
Exceptional Items / Prior Period Adjustment			.00	.00
PROFIT/(LOSS) BEFORE TAX	36.05	74.71	33.87	265.54
Tax expense:				
Current tax	-9.37	-42.13	-9.69	-66.64
Deferred tax	-3.86	-16.36	-.63	-10.41
Short / (Excess) Tax Provision	.00	-11.89	-1.22	-11.89
PROFIT (LOSS) FOR THE PERIOD	22.82	4.34	22.33	176.61
OTHER COMPREHENSIVE INCOME				
Items that will not be reclassified to profit or loss in Subsequent Periods :				
Remeasurement gains/(losses) on post employment defined benefit plans	.00	8.11	.00	8.11
Fair value changes of Investments	17.84	74.61	19.63	74.61
Income tax relating to items that will not be reclassified to profit or loss	-2.32	-16.38	-9.31	-16.38
TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	15.52	66.35	10.33	66.35
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	38.35	70.68	32.66	242.95
share)	966.10	966.10	966.10	966.10
EARNINGS PER EQUITY SHARE				
Basic	0.37	0.04	0.23	1.83
Diluted	0.37	0.04	0.23	1.83

For Sandu Pharmaceuticals Ltd


Balram Viswanathan
Managing Director

DIN : 10245195

Place :- Mumbai
Date :- 11th Aug 2026



Regd. Office & Factory : Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Pilerne, Marra, Saligao, Bardez, Goa - 403511.

Tel.: +91 832 6715000 / 05 / 36 / 2407475, E-mail: sandupharma@sandu.in

CIN:L24233GA1985PLC001587



1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. “Ayurvedic Property Medicines”. Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 11/08/2026.
4. The Figures for the quarter ended 30th June, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the first quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.

For Sandu Pharmaceuticals Ltd



BALRAM VISWANATHAN
Managing Director
DIN no: - 10245195

Date: - 11/08/2026